Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combinatorial Therapy to Induce an HIV Remission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04357821
Recruitment Status : Recruiting
First Posted : April 22, 2020
Last Update Posted : August 11, 2020
Sponsor:
Collaborators:
amfAR, The Foundation for AIDS Research
International AIDS Vaccine Initiative
Ichor Medical Systems
NIH Vaccine Research Center
Rockefeller University
Mologen AG
GeoVax, Inc.
Information provided by (Responsible Party):
Steven Deeks, University of California, San Francisco

Brief Summary:
Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).

Condition or disease Intervention/treatment Phase
HIV/AIDS Drug: Combination Intervention Phase 1 Phase 2

Detailed Description:

The investigators will perform a single arm study of twenty individuals with HIV infection on effective ART. All participants will receive a combination regimen administered during ART and then undergo an analytic treatment interruption. Our strategy has five stages

  1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4
  2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12
  3. MVA/HIV62B (MVA62B) boost at Week 20
  4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)
  5. ATI with single dose of VRC07 and 10-1074 at Week 34

Follow-up off ART will occur through at least Week 46 (expected) and on or off ART (depending on outcome) through Week 86.

Should this approach work, viral load would be expected to rebound in all individuals a few weeks after the bNAb levels decrease to sub-therapeutic levels. This acute rebound would be followed by a new lower viral load set-point and perhaps a long-term remission.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission
Estimated Study Start Date : September 2020
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Combination intervention arm
All volunteers will receive the combination intervention outlined above.
Drug: Combination Intervention
  1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4
  2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12
  3. MVA/HIV62B (MVA62B) boost at Week 20
  4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)
  5. ATI with single dose of VRC07 and 10-1074 at Week 34




Primary Outcome Measures :
  1. Proportion of participants who experience a new grade 3 or greater adverse event [ Time Frame: Week 0 through 86 ]
  2. Proportion of participants achieving post-treatment control. [ Time Frame: Week 34 through 86 ]

    This will be defined as:

    1. Participants who fail to show any consistent rebound above 400 copies RNA/mL between Week 12 of the ATI (when bNAb levels wane) and Week 36 of the ATI
    2. Participants who exhibit a rebound and eventually achieve 24 weeks of virus control will be considered as having achieved post-treatment control


Secondary Outcome Measures :
  1. Occurrence of any unsolicited adverse events for 28 days after administration of each study agent [ Time Frame: Week 0 through 62 ]
  2. Occurrence of any serious adverse events, medically attended adverse event, and potentially immune-mediated medical condition from the time of administration of the first study injection through 12 months after administration of the final study injection [ Time Frame: Week 0 through 86 ]
  3. Occurrence of two consecutive measurements HIV RNA >200 copies/mL using conventional assays [ Time Frame: Week 34 to 86 ]
  4. Resumptions of antiretroviral therapy after treatment interruption and the events that trigger them [ Time Frame: Week 34 to 86 ]
  5. Frequency of confirmed declines (two consecutive measurements) in CD4+ T cell counts (> 50%) [ Time Frame: Week 34 to 86 ]
  6. Frequency of confirmed declines (two consecutive measurements) to below 350 cells/mm3 [ Time Frame: Week 34 to 86 ]
  7. Proportion experiencing any clinically defined episode of acute retroviral syndrome [ Time Frame: Week 34 to 86 ]
  8. Magnitude of T cell responses [ Time Frame: Week 14 ]
  9. Breadth of T cell responses [ Time Frame: Week 14 ]
    The proportion of participants with at least one additional epitope response at week 14 (2 weeks after last vaccination) compared to their baseline response



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 67 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  1. Willing and able to provide written informed consent.
  2. Age ≤67 years at the time of enrollment for those who started treatment during early infection and <65 years for those who started treatment during chronic infection.
  3. Documented HIV-1 infection.
  4. On continuous antiretroviral therapy for at least 12 months without any interruptions of greater than 14 consecutive days within the last 1 year, and on a stable regimen that does not include an non-nucleoside reverse transcriptase inhibitor (NNRTI) for at least 4 weeks, without plans to modify ART during the study period.
  5. Screening plasma HIV RNA levels below the level of quantification on all available determinations in past 24 months.
  6. Screening CD4+ T-cell count ≥ 500 cells/mm3.

Key Exclusion Criteria

  1. Subjects receiving a non-nucleoside reverse transcriptase inhibitor
  2. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
  3. High-level resistance to both 10-1074 and VRC-07 as defined using the PhenoSense Neutralizing Antibody Assay (Monogram Biosciences).
  4. Any history of an HIV-associated malignancy, including Kaposi's sarcoma and any type of lymphoma, or virus-associated cancers.
  5. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months.
  6. CD4+ T cell nadir <350 cells/mm3 during the chronic phase of infection (beginning 6 months following the estimated infection date and confirmed on repeat testing).
  7. Active hepatitis B (HBV) infection defined as positive HBV surface antigen test.

9. Active hepatitis C (HCV) infection. 10. Presence of significant abnormalities on electrocardiogram. 11. History of potential immune-mediated medical conditions. Individuals with isolated Raynaud's phenomenon or localized disease requiring topical therapy alone will not be excluded.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04357821


Contacts
Layout table for location contacts
Contact: Steven G Deeks, MD 415-476-4082 ext 404 steven.deeks@ucsf.edu
Contact: Rebecca Hoh, MS, RD 415-476-4082 ext 139 rebecca.hoh@ucsf.edu

Locations
Layout table for location information
United States, California
Zuckerberg San Francisco General Hospital, University of California San Francisco Recruiting
San Francisco, California, United States, 94110
Contact: Rebecca Hoh    415-476-4082 ext 139    rebecca.hoh@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
amfAR, The Foundation for AIDS Research
International AIDS Vaccine Initiative
Ichor Medical Systems
NIH Vaccine Research Center
Rockefeller University
Mologen AG
GeoVax, Inc.
Layout table for additonal information
Responsible Party: Steven Deeks, Professor in Residence, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04357821    
Other Study ID Numbers: 18-26957
First Posted: April 22, 2020    Key Record Dates
Last Update Posted: August 11, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases